Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by MERRICK I ROSS and JEFFREY E GERSHENWALD.
MERRICK I ROSS
Connection Strength
6.818
JEFFREY E GERSHENWALD
  1. Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. Clin Dermatol. 2013 May-Jun; 31(3):298-310.
    View in: PubMed
    Score: 0.449
  2. Evidence-based treatment of early-stage melanoma. J Surg Oncol. 2011 Sep; 104(4):341-53.
    View in: PubMed
    Score: 0.400
  3. Sentinel-lymph-node biopsy for cutaneous melanoma. N Engl J Med. 2011 May 05; 364(18):1738-45.
    View in: PubMed
    Score: 0.391
  4. Sentinel lymph node biopsy for melanoma: critical assessment at its twentieth anniversary. Surg Oncol Clin N Am. 2011 Jan; 20(1):57-78.
    View in: PubMed
    Score: 0.382
  5. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol. 2008 Sep 10; 26(26):4296-303.
    View in: PubMed
    Score: 0.321
  6. How should we view the results of the Multicenter Selective Lymphadenectomy Trial-1 (MSLT-1)? Ann Surg Oncol. 2008 Mar; 15(3):670-3.
    View in: PubMed
    Score: 0.312
  7. Is sentinel-node biopsy superior to nodal observation in melanoma? Nat Clin Pract Oncol. 2007 May; 4(5):278-9.
    View in: PubMed
    Score: 0.294
  8. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel). 2023 Jul 15; 15(14).
    View in: PubMed
    Score: 0.227
  9. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res. 2020 04 15; 26(8):1886-1895.
    View in: PubMed
    Score: 0.179
  10. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 Nov; 67(6):472-492.
    View in: PubMed
    Score: 0.153
  11. Cost effectiveness of adjuvant interferon in node-positive melanoma. J Clin Oncol. 2007 Jun 10; 25(17):2442-8.
    View in: PubMed
    Score: 0.075
  12. Accuracy of lymphatic mapping and sentinel lymph node biopsy after previous wide local excision in patients with primary melanoma. Cancer. 2006 Dec 01; 107(11):2647-52.
    View in: PubMed
    Score: 0.072
  13. Acne vulgaris: false-positive finding on integrated 18F-FDG PET/CT in a patient with melanoma. AJR Am J Roentgenol. 2006 Jul; 187(1):W117-9.
    View in: PubMed
    Score: 0.070
  14. Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer. 2006 May 01; 106(9):2012-20.
    View in: PubMed
    Score: 0.069
  15. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. Cancer. 2006 Feb 15; 106(4):900-6.
    View in: PubMed
    Score: 0.068
  16. The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol. 2005 Jul 20; 23(21):4588-90.
    View in: PubMed
    Score: 0.065
  17. Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol. 2005 Aug; 12(8):587-96.
    View in: PubMed
    Score: 0.065
  18. Re: Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma, Thomas and Clark. Eur J Surg Oncol. 2005 Apr; 31(3):323-4.
    View in: PubMed
    Score: 0.064
  19. A critical assessment of adjuvant radiotherapy for inguinal lymph node metastases from melanoma. Ann Surg Oncol. 2004 Dec; 11(12):1079-84.
    View in: PubMed
    Score: 0.063
  20. Lymphatic mapping in the molecular era. Ann Surg Oncol. 2004 Apr; 11(4):362-74.
    View in: PubMed
    Score: 0.060
  21. Primary tumor site for localized Merkel cell carcinoma drives different management strategies without impacting oncologic outcomes. Radiother Oncol. 2023 11; 188:109892.
    View in: PubMed
    Score: 0.057
  22. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol. 2003 Jun; 10(5):569-74.
    View in: PubMed
    Score: 0.056
  23. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol. 2023 Aug; 128(2):313-321.
    View in: PubMed
    Score: 0.056
  24. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2023 Mar; 615(7953):E23.
    View in: PubMed
    Score: 0.055
  25. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2023 Jan; 613(7945):E3.
    View in: PubMed
    Score: 0.055
  26. Sphincter-sparing local excision and adjuvant radiation for anal-rectal melanoma. J Clin Oncol. 2002 Dec 01; 20(23):4555-8.
    View in: PubMed
    Score: 0.054
  27. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. 2022 11; 611(7934):155-160.
    View in: PubMed
    Score: 0.054
  28. Correction to: Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Aug; 29(8):5241-5242.
    View in: PubMed
    Score: 0.053
  29. Implications of lymphatic drainage to unusual sentinel lymph node sites in patients with primary cutaneous melanoma. Cancer. 2002 Jul 15; 95(2):354-60.
    View in: PubMed
    Score: 0.053
  30. Presence of the human leukocyte antigen class II gene DRB1*1101 predicts interferon gamma levels and disease recurrence in melanoma patients. Ann Surg Oncol. 2002 Jul; 9(6):587-93.
    View in: PubMed
    Score: 0.053
  31. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. 2022 06; 606(7915):797-803.
    View in: PubMed
    Score: 0.053
  32. Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2002 Mar 15; 52(4):964-72.
    View in: PubMed
    Score: 0.052
  33. Outcomes After Sphincter-Sparing Local Therapy for Anorectal Melanoma: 1989 to 2020. Pract Radiat Oncol. 2022 Sep-Oct; 12(5):437-445.
    View in: PubMed
    Score: 0.052
  34. Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). Ann Surg Oncol. 2022 Jun; 29(6):3694-3708.
    View in: PubMed
    Score: 0.051
  35. Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. Science. 2021 Dec 24; 374(6575):1632-1640.
    View in: PubMed
    Score: 0.051
  36. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol. 2022 07; 142(7):2046-2049.e3.
    View in: PubMed
    Score: 0.051
  37. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol. 2022 Mar; 125(4):719-729.
    View in: PubMed
    Score: 0.051
  38. Identification of MicroRNA-mRNA Networks in Melanoma and Their Association with PD-1 Checkpoint Blockade Outcomes. Cancers (Basel). 2021 Oct 22; 13(21).
    View in: PubMed
    Score: 0.050
  39. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol. 2021 Jul; 28(7):3480-3489.
    View in: PubMed
    Score: 0.049
  40. Functional annotation of melanoma risk loci identifies novel susceptibility genes. Carcinogenesis. 2020 06 17; 41(4):452-457.
    View in: PubMed
    Score: 0.046
  41. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol. 2020 05 01; 38(13):1429-1441.
    View in: PubMed
    Score: 0.045
  42. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.044
  43. Correlation of Tumor Burden in Sentinel Lymph Nodes with Tumor Burden in Nonsentinel Lymph Nodes and Survival in Cutaneous Melanoma. Clin Cancer Res. 2019 12 15; 25(24):7585-7593.
    View in: PubMed
    Score: 0.044
  44. Prognostic model for patient survival in primary anorectal mucosal melanoma: stage at presentation determines relevance of histopathologic features. Mod Pathol. 2020 03; 33(3):496-513.
    View in: PubMed
    Score: 0.043
  45. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019 07; 20(7):e378-e389.
    View in: PubMed
    Score: 0.043
  46. Role of Immune Response, Inflammation, and Tumor Immune Response-Related Cytokines/Chemokines in Melanoma Progression. J Invest Dermatol. 2019 11; 139(11):2352-2358.e3.
    View in: PubMed
    Score: 0.043
  47. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1941.
    View in: PubMed
    Score: 0.041
  48. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 Dec; 24(12):1942.
    View in: PubMed
    Score: 0.041
  49. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018 11; 24(11):1649-1654.
    View in: PubMed
    Score: 0.041
  50. A model for predicting low probability of nonsentinel lymph node positivity in melanoma patients with a single positive sentinel lymph node. J Surg Oncol. 2018 Nov; 118(6):922-927.
    View in: PubMed
    Score: 0.041
  51. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res. 2018 09 15; 24(18):4416-4428.
    View in: PubMed
    Score: 0.040
  52. The Great Debate at "Melanoma Bridge", Napoli, December 2nd, 2017. J Transl Med. 2018 04 17; 16(1):101.
    View in: PubMed
    Score: 0.040
  53. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
    View in: PubMed
    Score: 0.039
  54. Association between Body Mass Index, C-Reactive Protein Levels, and Melanoma Patient Outcomes. J Invest Dermatol. 2017 08; 137(8):1792-1795.
    View in: PubMed
    Score: 0.037
  55. Tumor Thickness and Mitotic Rate Robustly Predict Melanoma-Specific Survival in Patients with Primary Vulvar Melanoma: A Retrospective Review of 100 Cases. Clin Cancer Res. 2017 04 15; 23(8):2093-2104.
    View in: PubMed
    Score: 0.036
  56. Melanoma Expression Genes Identified through Genome-Wide Association Study of?Breslow Tumor Thickness. J Invest Dermatol. 2017 01; 137(1):253-257.
    View in: PubMed
    Score: 0.035
  57. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol. 2016 05 20; 34(15):1741-7.
    View in: PubMed
    Score: 0.034
  58. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. J Clin Oncol. 2016 Apr 01; 34(10):1079-86.
    View in: PubMed
    Score: 0.034
  59. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. J Surg Oncol. 2015 Dec; 112(8):834-40.
    View in: PubMed
    Score: 0.033
  60. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk, and Outcomes. J Invest Dermatol. 2015 Sep; 135(9):2266-2272.
    View in: PubMed
    Score: 0.032
  61. C-reactive protein as a marker of melanoma progression. J Clin Oncol. 2015 Apr 20; 33(12):1389-96.
    View in: PubMed
    Score: 0.032
  62. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer. 2015 Apr 15; 136(8):1874-80.
    View in: PubMed
    Score: 0.031
  63. Is surveillance imaging effective for detecting surgically treatable recurrences in patients with melanoma? A comparative analysis of stage-specific surveillance strategies. Ann Surg. 2014 Jun; 259(6):1215-22.
    View in: PubMed
    Score: 0.030
  64. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol. 2014 Apr; 21(4):1075-81.
    View in: PubMed
    Score: 0.030
  65. Impact of the 2009 (7th edition) AJCC melanoma staging system in the classification of thin cutaneous melanomas. Biomed Res Int. 2013; 2013:898719.
    View in: PubMed
    Score: 0.029
  66. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013 Aug; 23(4):290-7.
    View in: PubMed
    Score: 0.029
  67. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol. 2013 Nov; 20(12):3961-8.
    View in: PubMed
    Score: 0.028
  68. The new melanoma staging system. Semin Cutan Med Surg. 2003 Mar; 22(1):42-54.
    View in: PubMed
    Score: 0.028
  69. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2012 Dec 15; 18(24):6758-70.
    View in: PubMed
    Score: 0.027
  70. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res. 2012 Oct; 22(5):376-85.
    View in: PubMed
    Score: 0.027
  71. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model. J Am Coll Surg. 2012 Apr; 214(4):608-17; discussion 617-9.
    View in: PubMed
    Score: 0.026
  72. Mapping FACT-melanoma quality-of-life scores to EQ-5D health utility weights. Value Health. 2011 Sep-Oct; 14(6):900-6.
    View in: PubMed
    Score: 0.025
  73. Factors predictive of the status of sentinel lymph nodes in melanoma patients from a large multicenter database. Ann Surg Oncol. 2011 Dec; 18(13):3593-600.
    View in: PubMed
    Score: 0.025
  74. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res. 2011 Jul 15; 17(14):4882-91.
    View in: PubMed
    Score: 0.025
  75. Outcomes in pediatric melanoma: comparing prepubertal to adolescent pediatric patients. Ann Surg. 2011 Jun; 253(6):1211-5.
    View in: PubMed
    Score: 0.025
  76. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011 Jun 01; 29(16):2199-205.
    View in: PubMed
    Score: 0.024
  77. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst. 2011 Jan 19; 103(2):129-42.
    View in: PubMed
    Score: 0.024
  78. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010 Nov; 63(5):751-61.
    View in: PubMed
    Score: 0.023
  79. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer. 2010 May 01; 116(9):2234-41.
    View in: PubMed
    Score: 0.023
  80. Conditional survival estimates improve over 5 years for melanoma survivors with node-positive disease. Ann Surg Oncol. 2010 Aug; 17(8):2015-23.
    View in: PubMed
    Score: 0.023
  81. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol. 2010 May 10; 28(14):2452-9.
    View in: PubMed
    Score: 0.023
  82. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010 Oct; 17(10):2764-72.
    View in: PubMed
    Score: 0.023
  83. Factors associated with false-negative sentinel lymph node biopsy in melanoma patients. Ann Surg Oncol. 2010 Mar; 17(3):709-17.
    View in: PubMed
    Score: 0.022
  84. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009 Dec 20; 27(36):6199-206.
    View in: PubMed
    Score: 0.022
  85. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer. 2009 Jun 01; 115(11):2505-13.
    View in: PubMed
    Score: 0.021
  86. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol. 2009 May; 60(5):872-5.
    View in: PubMed
    Score: 0.021
  87. A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence. Melanoma Res. 2009 Feb; 19(1):42-9.
    View in: PubMed
    Score: 0.021
  88. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys. 2009 Apr 01; 73(5):1376-82.
    View in: PubMed
    Score: 0.020
  89. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol. 2008 Jun 18; 6:63.
    View in: PubMed
    Score: 0.020
  90. Prospective assessment of the reliability, validity, and sensitivity to change of the Functional Assessment of Cancer Therapy-Melanoma questionnaire. Cancer. 2008 May 15; 112(10):2249-57.
    View in: PubMed
    Score: 0.020
  91. Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease. Cancer. 2008 May 01; 112(9):2030-7.
    View in: PubMed
    Score: 0.020
  92. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg. 2008 Mar; 195(3):363-8; discussion 368-9.
    View in: PubMed
    Score: 0.020
  93. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol. 2007 Oct; 14(10):2867-75.
    View in: PubMed
    Score: 0.019
  94. Polymorphisms in the DNA repair genes XPC, XPD, and XPG and risk of cutaneous melanoma: a case-control analysis. Cancer Epidemiol Biomarkers Prev. 2006 Dec; 15(12):2526-32.
    View in: PubMed
    Score: 0.018
  95. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006 Sep 25; 166(17):1907-14.
    View in: PubMed
    Score: 0.018
  96. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol. 2007 Feb; 127(2):276-80.
    View in: PubMed
    Score: 0.018
  97. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. J Clin Oncol. 2006 Jun 20; 24(18):2858-65.
    View in: PubMed
    Score: 0.017
  98. Invasive squamous cell carcinoma of the skin: defining a high-risk group. Ann Surg Oncol. 2006 Jul; 13(7):902-9.
    View in: PubMed
    Score: 0.017
  99. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006 Sep; 27(9):1894-901.
    View in: PubMed
    Score: 0.017
  100. Impact of sentinel node status and other risk factors on the clinical outcome of head and neck melanoma patients. Arch Otolaryngol Head Neck Surg. 2006 Apr; 132(4):370-3.
    View in: PubMed
    Score: 0.017
  101. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics. 2006 Apr; 16(4):253-63.
    View in: PubMed
    Score: 0.017
  102. Hepatic resection for metastatic melanoma: distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol. 2006 May; 13(5):712-20.
    View in: PubMed
    Score: 0.017
  103. In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis. J Natl Cancer Inst. 2005 Dec 21; 97(24):1822-31.
    View in: PubMed
    Score: 0.017
  104. Intraoperative frozen-section evaluation can reduce accuracy of pathologic assessment of sentinel nodes in melanoma patients. J Am Coll Surg. 2005 Nov; 201(5):821-3; author reply 823-4.
    View in: PubMed
    Score: 0.017
  105. Combined-modality therapy for patients with regional nodal metastases from melanoma. Int J Radiat Oncol Biol Phys. 2006 Jan 01; 64(1):106-13.
    View in: PubMed
    Score: 0.017
  106. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol. 2005 Sep 01; 23(25):6054-62.
    View in: PubMed
    Score: 0.016
  107. Melanoma metastatic to cervical lymph nodes: Can radiotherapy replace formal dissection after local excision of nodal disease? Head Neck. 2005 Aug; 27(8):718-21.
    View in: PubMed
    Score: 0.016
  108. Contralateral prophylactic mastectomy. Predictors of significant histologic findings. Cancer. 2004 Nov 01; 101(9):1977-86.
    View in: PubMed
    Score: 0.016
  109. Lessons learned from the Sunbelt Melanoma Trial. J Surg Oncol. 2004 Jul 01; 86(4):212-23.
    View in: PubMed
    Score: 0.015
  110. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin. 2004 May-Jun; 54(3):131-49; quiz 182-4.
    View in: PubMed
    Score: 0.015
  111. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004 Apr 01; 100(7):1478-83.
    View in: PubMed
    Score: 0.015
  112. Elective radiotherapy provides regional control for patients with cutaneous melanoma of the head and neck. Cancer. 2004 Jan 15; 100(2):383-9.
    View in: PubMed
    Score: 0.015
  113. p53 codon 72 Arg homozygotes are associated with an increased risk of cutaneous melanoma. J Invest Dermatol. 2003 Dec; 121(6):1510-4.
    View in: PubMed
    Score: 0.015
  114. Adjuvant irradiation for cervical lymph node metastases from melanoma. Cancer. 2003 Apr 01; 97(7):1789-96.
    View in: PubMed
    Score: 0.014
  115. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar; 19(2):102-6.
    View in: PubMed
    Score: 0.014
  116. Repair of UV light-induced DNA damage and risk of cutaneous malignant melanoma. J Natl Cancer Inst. 2003 Feb 19; 95(4):308-15.
    View in: PubMed
    Score: 0.014
  117. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol. 2003; 21(1):43-52.
    View in: PubMed
    Score: 0.014
  118. DNA repair gene XRCC3 241Met variant is not associated with risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2002 Oct; 11(10 Pt 1):1142-3.
    View in: PubMed
    Score: 0.013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.